XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash Flows From Operating Activities:    
Net (loss)/earnings $ (9,009) $ 6,278
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization, net 7,720 7,296
Deferred income taxes (1,298) (1,961)
Stock-based compensation 387 391
Impairment charges 1,010 226
Divestiture gains and royalties (838) (639)
Acquired IPRD 13,343 313
Equity investment (gains)/losses (221) 213
Other adjustments 123 260
Changes in operating assets and liabilities:    
Receivables 121 (487)
Inventories (661) (554)
Accounts payable (333) (246)
Rebates and discounts 1,889 1,115
Income taxes payable (1,381) (1,647)
Other (101) (950)
Net cash provided by operating activities 10,751 9,608
Cash Flows From Investing Activities:    
Sale and maturities of marketable debt securities 1,060 692
Purchase of marketable debt securities (398) (1,057)
Proceeds from sales of equity investments 60 215
Capital expenditures (870) (879)
Divestiture and other proceeds 766 668
Acquisition and other payments, net of cash acquired (21,774) (588)
Net cash used in investing activities (21,156) (949)
Cash Flows From Financing Activities:    
Proceeds from issuance of short-term debt obligations 2,987 0
Repayments of short-term debt obligations (3,000) 0
Other short-term financing obligations, net 504 233
Proceeds from issuance of long-term debt 12,883 0
Repayments of long-term debt (2,873) (1,879)
Repurchase of common stock 0 (5,155)
Dividends (3,645) (3,584)
Stock option proceeds and other, net (87) 2
Net cash provided by/(used in) financing activities 6,769 (10,383)
Effect of exchange rates on cash, cash equivalents and restricted cash 10 (33)
Decrease in cash, cash equivalents and restricted cash (3,626) (1,757)
Cash, cash equivalents and restricted cash at beginning of period 11,519 9,325
Cash, cash equivalents and restricted cash at end of period $ 7,893 $ 7,568